Artemisinin-based combination therapy for ... - The Cochrane Library
Artemisinin-based combination therapy for ... - The Cochrane Library
Artemisinin-based combination therapy for ... - The Cochrane Library
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Analysis 10.5. Comparison 10 Artemether-lumefantrine vs Artesunate plus sulfadoxine-pyrimethamine, Outcome 5 P.<br />
vivax parasitaemia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 180<br />
Analysis 10.6. Comparison 10 Artemether-lumefantrine vs Artesunate plus sulfadoxine-pyrimethamine, Outcome 6<br />
Sensitivity analysis Total Failure Day 28 PCR unadjusted. . . . . . . . . . . . . . . . . . . 181<br />
Analysis 10.7. Comparison 10 Artemether-lumefantrine vs Artesunate plus sulfadoxine-pyrimethamine, Outcome 7<br />
Sensitivity analysis: Total Failure Day 28 PCR adjusted. . . . . . . . . . . . . . . . . . . . 182<br />
Analysis 11.1. Comparison 11 Artemether-lumefantrine vs Amodiaquine plus sulfadoxine-pyrimethamine, Outcome 1<br />
Total Failure (P. falciparum) Day 28 PCR unadjusted. . . . . . . . . . . . . . . . . . . . 183<br />
Analysis 11.2. Comparison 11 Artemether-lumefantrine vs Amodiaquine plus sulfadoxine-pyrimethamine, Outcome 2<br />
Total Failure (P. falciparum) Day 28 PCR adjusted. . . . . . . . . . . . . . . . . . . . . 184<br />
Analysis 11.3. Comparison 11 Artemether-lumefantrine vs Amodiaquine plus sulfadoxine-pyrimethamine, Outcome 3<br />
Total Failure (P. falciparum) Day 42 PCR unadjusted. . . . . . . . . . . . . . . . . . . . 185<br />
Analysis 11.4. Comparison 11 Artemether-lumefantrine vs Amodiaquine plus sulfadoxine-pyrimethamine, Outcome 4<br />
Total Failure (P. falciparum) Day 42 PCR adjusted. . . . . . . . . . . . . . . . . . . . . 185<br />
Analysis 11.5. Comparison 11 Artemether-lumefantrine vs Amodiaquine plus sulfadoxine-pyrimethamine, Outcome 5<br />
Gametocyte carriage. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 186<br />
Analysis 11.6. Comparison 11 Artemether-lumefantrine vs Amodiaquine plus sulfadoxine-pyrimethamine, Outcome 6<br />
Gametocyte development (in those negative at baseline). . . . . . . . . . . . . . . . . . . . 187<br />
Analysis 11.7. Comparison 11 Artemether-lumefantrine vs Amodiaquine plus sulfadoxine-pyrimethamine, Outcome 7<br />
Anaemia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 188<br />
Analysis 11.8. Comparison 11 Artemether-lumefantrine vs Amodiaquine plus sulfadoxine-pyrimethamine, Outcome 8<br />
Serious adverse events (including deaths). . . . . . . . . . . . . . . . . . . . . . . . . 188<br />
Analysis 11.9. Comparison 11 Artemether-lumefantrine vs Amodiaquine plus sulfadoxine-pyrimethamine, Outcome 9<br />
Early vomiting. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 189<br />
Analysis 12.1. Comparison 12 Artesunate plus amodiaquine vs Artesunate plus sulfadoxine-pyrimethamine, Outcome 1<br />
Total Failure (P. falciparum) Day 28 PCR unadjusted. . . . . . . . . . . . . . . . . . . . 190<br />
Analysis 12.2. Comparison 12 Artesunate plus amodiaquine vs Artesunate plus sulfadoxine-pyrimethamine, Outcome 2<br />
Total Failure (P. falciparum) Day 28 PCR adjusted. . . . . . . . . . . . . . . . . . . . . 191<br />
Analysis 12.3. Comparison 12 Artesunate plus amodiaquine vs Artesunate plus sulfadoxine-pyrimethamine, Outcome 3<br />
Gametocyte carriage. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 192<br />
Analysis 12.4. Comparison 12 Artesunate plus amodiaquine vs Artesunate plus sulfadoxine-pyrimethamine, Outcome 4<br />
Proportion of participants with anaemia. . . . . . . . . . . . . . . . . . . . . . . . . 193<br />
Analysis 12.5. Comparison 12 Artesunate plus amodiaquine vs Artesunate plus sulfadoxine-pyrimethamine, Outcome 5<br />
Serious adverse events (including deaths). . . . . . . . . . . . . . . . . . . . . . . . . 194<br />
Analysis 13.1. Comparison 13 Artesunate plus amodiaquine vs Amodiaquine plus sulfadoxine-pyrimethamine, Outcome 1<br />
Total Failure (P. falciparum) Day 28 PCR unadjusted. . . . . . . . . . . . . . . . . . . . 195<br />
Analysis 13.2. Comparison 13 Artesunate plus amodiaquine vs Amodiaquine plus sulfadoxine-pyrimethamine, Outcome 2<br />
Total Failure (P. falciparum) Day 28 PCR adjusted. . . . . . . . . . . . . . . . . . . . . 196<br />
Analysis 13.3. Comparison 13 Artesunate plus amodiaquine vs Amodiaquine plus sulfadoxine-pyrimethamine, Outcome 3<br />
Gametocyte development. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 197<br />
Analysis 13.4. Comparison 13 Artesunate plus amodiaquine vs Amodiaquine plus sulfadoxine-pyrimethamine, Outcome 4<br />
Gametocyte carriage. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 197<br />
Analysis 13.5. Comparison 13 Artesunate plus amodiaquine vs Amodiaquine plus sulfadoxine-pyrimethamine, Outcome 5<br />
Anaemia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 199<br />
Analysis 13.6. Comparison 13 Artesunate plus amodiaquine vs Amodiaquine plus sulfadoxine-pyrimethamine, Outcome 6<br />
Serious adverse events (including deaths). . . . . . . . . . . . . . . . . . . . . . . . . 200<br />
Analysis 14.1. Comparison 14 Dihydroartemisinin-piperaquine dose analysis: 3 dose vs 4 dose regimen, Outcome 1 Total<br />
Failure PCR unadjusted. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 200<br />
Analysis 14.2. Comparison 14 Dihydroartemisinin-piperaquine dose analysis: 3 dose vs 4 dose regimen, Outcome 2 Total<br />
Failure PCR adjusted. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 201<br />
Analysis 15.1. Comparison 15 Dihydroartemisinin-piperaquine dose analysis (versus Artesunate plus mefloquine),<br />
Outcome 1 Total Failure Day 63 PCR unadjusted. . . . . . . . . . . . . . . . . . . . . . 202<br />
<strong>Artemisinin</strong>-<strong>based</strong> <strong>combination</strong> <strong>therapy</strong> <strong>for</strong> treating uncomplicated malaria (Review)<br />
Copyright © 2009 <strong>The</strong> <strong>Cochrane</strong> Collaboration. Published by John Wiley & Sons, Ltd.<br />
iv